INFUSYSTEM HOLDINGS INC
INFUNYSE AMERICANTrading Snapshot
- Day Range
- $14.23 β $14.39
- 52-Week Range
- $7.29 β $14.41
- Volume (shares)
- 7,272
- Avg Volume (shares)
- β
- Shares Outstanding
- 19.9M
- Next Earnings
- 2026-11-03
Fundamentals Snapshot
- Annual Revenue
- $143M
- Last Q Revenue
- $37M
- P/E Ratio
- 34.1
- P/S Ratio
- 2.0x
- EPS (TTM)
- $0.42
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β3.0%
INFUSYSTEM HOLDINGS INC
INFUAbout INFUSYSTEM HOLDINGS INC
InfuSystem Holdings, Inc. delivers infusion pumps, along with associated products and support services, to clients across the United States and Canada. The enterprise operates through two principal divisions: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). The ITS segment specializes in providing electronic ambulatory infusion devices and accompanying disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy facilities. These devices are crucial for managing various cancers, including colorectal cancer, as well as for pain management and other therapeutic needs. Moreover, the company markets, leases, and rents out a selection of new and pre-owned infusion pumps (both pole-mounted and ambulatory) and other vital durable medical equipment. It also sells consumables essential for treatment. InfuSystem further extends its offerings to include biomedical recertification, maintenance, and repair services for oncology practices and diverse alternative care settings, such as home care and home infusion providers, skilled nursing facilities, pain centers, and hospitals. Additionally, InfuSystem furnishes both local and field-based customer assistance and manages dedicated pump service and repair facilities. The company was founded in 2005 and maintains its corporate headquarters in Rochester Hills, Michigan.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
βLatest News & Updates
News unavailable.